Journal of Physiology and Biochemistry

, Volume 71, Issue 3, pp 471–478 | Cite as

Lipodystrophies: adipose tissue disorders with severe metabolic implications

  • Víctor A. Cortés
  • Marta Fernández-Galilea
Mini Review


Lipodystrophy encompass a group of heterogeneous disorders consisting in marked reduction, absence, and/or the redistribution of adipose tissue. Lipodystrophy is frequently complicated with severe insulin resistance, diabetes, hyperlipidemia, and fatty liver. Anatomically, lipodystrophies can be partial or generalized. Etiologically, they can be congenital or acquired. Lipodystrophy diagnosis can be challenging, and it has been suggested that partial forms can be easily misdiagnosed as common central obesity with associated metabolic syndrome. Conventional insulin-sensitizing approaches usually fail to fully ameliorate insulin resistance in lipodystrophic patients. Leptin replacement is an approved therapy for the metabolic complications of congenital generalized lipodystrophy. Novel nutritional interventions are promising complementary approaches for treating lipodystrophy metabolic complications.


Lipodystrophy Adipose tissue Insulin resistance Hypertriglyceridemia Leptin Treatment Nutrition 


  1. 1.
    Agarwal AK, Garg A (2002) A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab 87:408–411PubMedGoogle Scholar
  2. 2.
    Andrés V, González JM (2009) Role of A-type lamins in signaling, transcription, and chromatin organization. J Cell Biol 187:945–957PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Asilmaz E, Cohen P, Miyazaki M, Dobrzyn P, Ueki K, Fayzikhodjaeva G, Soukas AA, Kahn CR, Ntambi JM, Socci ND, Friedman JM (2004) Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. J Clin Investig 113:414–424PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Berardinelli W (1954) An undiagnosed endocrinometabolic syndrome: report of 2 cases. J Clin Endocrinol Metab 14:193–204CrossRefPubMedGoogle Scholar
  5. 5.
    Cao H, Hegele RA (2000) Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet 9:109–112CrossRefPubMedGoogle Scholar
  6. 6.
    Chong AY, Lupsa BC, Cochran EK, Gorden P (2010) Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia 53:27–35CrossRefPubMedGoogle Scholar
  7. 7.
    Colca JR, McDonald WG, Waldon DJ, Leone JW, Lull JM, Bannow CA, Lund ET, Mathews WR (2004) Identification of a novel mitochondrial protein (“mitoNEET”) cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol Endocrinol Metab 286:E252–E260CrossRefPubMedGoogle Scholar
  8. 8.
    Cortés VA, Cautivo KM, Rong S, Garg A, Horton JD, Agarwal AK (2014) Leptin ameliorates insulin resistance and hepatic steatosis in Agpat2−/− lipodystrophic mice independent of hepatocyte leptin receptors. J Lipid Res 55:276–288PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Cortes VA, Smalley SV, Goldenberg D, Lagos CF, Hodgson MI, Santos JL (2014) Divergent metabolic phenotype between Two sisters with congenital generalized lipodystrophy due to double AGPAT2 homozygous mutations. A clinical, genetic and in silico study. PLoS One 9:e87173PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    de Medeiros D, Rocha E, Dantas Leite L, de Fatima Paiva Baracho M, Goretti do Nascimento Santos M, de Araujo DM, Cavalcante Franca M, da Silva CA, das Gracas Almeida M, Rezende AA, Marchini JS, Brandao-Neto J (2010) Effect of diet intervention and oral zinc supplementation on metabolic control in Berardinelli-Seip syndrome. Ann Nutr Metab 57:9–17Google Scholar
  11. 11.
    Decaudain A, Vantyghem MC, Guerci B, Hecart AC, Auclair M, Reznik Y, Narbonne H, Ducluzeau PH, Donadille B, Lebbe C, Bereziat V, Capeau J, Lascols O, Vigouroux C (2007) New metabolic phenotypes in laminopathies: LMNA mutations in patients with severe metabolic syndrome. J Clin Endocrinol Metab 92:4835–4844CrossRefPubMedGoogle Scholar
  12. 12.
    Domingo P, Gutierrez Mdel M, Gallego-Escuredo JM, Torres F, Mateo GM, Villarroya J, de los Santos I, Domingo JC, Villarroya F, Del Rio L, Estrada V, Giralt M (2014) Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular study. PLoS One 9:e89088PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Dunnigan MG, Cochrane MA, Kelly A, Scott JW (1974) Familial lipoatrophic diabetes with dominant transmission. A new syndrome. Q J Med 43:33–48PubMedGoogle Scholar
  14. 14.
    Dutour A, Roll P, Gaborit B, Courrier S, Alessi MC, Tregouet DA, Angelis F, Robaglia-Schlupp A, Lesavre N, Cau P, Levy N, Badens C, Morange PE (2011) High prevalence of laminopathies among patients with metabolic syndrome. Hum Mol Genet 20:3779–3786CrossRefPubMedGoogle Scholar
  15. 15.
    Ebihara K, Kusakabe T, Hirata M, Masuzaki H, Miyanaga F, Kobayashi N, Tanaka T, Chusho H, Miyazawa T, Hayashi T, Hosoda K, Ogawa Y, DePaoli AM, Fukushima M, Nakao K (2007) Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab 92:532–541CrossRefPubMedGoogle Scholar
  16. 16.
    Gandotra S, Le Dour C, Bottomley W, Cervera P, Giral P, Reznik Y, Charpentier G, Auclair M, Delepine M, Barroso I, Semple RK, Lathrop M, Lascols O, Capeau J, O'Rahilly S, Magre J, Savage DB, Vigouroux C (2011) Perilipin deficiency and autosomal dominant partial lipodystrophy. N Engl J Med 364:740–748PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Garg A (2011) Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab 96:3313–3325CrossRefPubMedGoogle Scholar
  18. 18.
    Goldenberg D, Santos JL, Hodgson MI, Cortes VA (2014) Novel physiological and therapeutic implications of leptin. Rev Med Chil 142:738–747CrossRefPubMedGoogle Scholar
  19. 19.
    Halberg N, Wernstedt-Asterholm I, Scherer PE (2008) The adipocyte as an endocrine cell. Endocrinol Metab Clin North Am 37:753PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Herbst KL, Tannock LR, Deeb SS, Purnell JQ, Brunzell JD, Chait A (2003) Kobberling type of familial partial lipodystrophy: an underrecognized syndrome. Diabetes Care 26:1819–1824CrossRefPubMedGoogle Scholar
  21. 21.
    Ishii J, Abe M, Kubo M, Sumimoto T, Hamada M, Hiwada K, Kokubu T, Osawa G (1989) Total lipodystrophy with heart failure and renal failure: report of a case. Jpn J Med 28:534–537CrossRefPubMedGoogle Scholar
  22. 22.
    Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P (2005) Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 54:1994–2002CrossRefPubMedGoogle Scholar
  23. 23.
    Javor ED, Moran SA, Young JR, Cochran EK, DePaoli AM, Oral EA, Turman MA, Blackett PR, Savage DB, O'Rahilly S, Balow JE, Gorden P (2004) Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy. J Clin Endocrinol Metab 89:3199–3207CrossRefPubMedGoogle Scholar
  24. 24.
    Khalife WI, Mourtada MC, Khalil J (2008) Dilated cardiomyopathy and myocardial infarction secondary to congenital generalized lipodystrophy. Tex Heart Inst J 35:196–199PubMedCentralPubMedGoogle Scholar
  25. 25.
    Kobberling J, Willms B, Kattermann R, Creutzfeldt W (1975) Lipodystrophy of the extremities. A dominantly inherited syndrome associated with lipatrophic diabetes. Humangenetik 29:111–120PubMedGoogle Scholar
  26. 26.
    Levy M, Thaiss CA, Katz MN, Suez J, Elinav E (2014) Inflammasomes and the microbiota-partners in the preservation of mucosal homeostasis. Semin Immunopathol 36:261–274CrossRefGoogle Scholar
  27. 27.
    Maguire M, Lungu A, Gorden P, Cochran E, Stratton P (2012) Pregnancy in a woman with congenital generalized lipodystrophy: leptin’s vital role in reproduction. Obstet Gynecol 119:452–455PubMedCentralCrossRefPubMedGoogle Scholar
  28. 28.
    McDuffie JR, Riggs PA, Calis KA, Freedman RJ, Oral EA, DePaoli AM, Yanovski JA (2004) Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. J Clin Endocrinol Metab 89:4258–4263PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    McNally M, Mannon RB, Javor ED, Swanson SJ, Hale DA, Gorden P, Kirk AD (2004) Successful renal transplantation in a patient with congenital generalized lipodystrophy: a case report. Am J Transplant 4:447–449CrossRefPubMedGoogle Scholar
  30. 30.
    Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, Kahn BB (2002) Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415:339–343CrossRefPubMedGoogle Scholar
  31. 31.
    Misra A, Garg A (2003) Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine (Baltimore) 82:129–146CrossRefGoogle Scholar
  32. 32.
    Misra A, Peethambaram A, Garg A (2004) Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore) 83:18–34CrossRefGoogle Scholar
  33. 33.
    Miyamoto L, Ebihara K, Kusakabe T, Aotani D, Yamamoto-Kataoka S, Sakai T, Aizawa-Abe M, Yamamoto Y, Fujikura J, Hayashi T, Hosoda K, Nakao K (2012) Leptin activates hepatic 5′-AMP-activated protein kinase through sympathetic nervous system and α1-adrenergic receptor: A potential mechanism for improvement of fatty liver in lipodystrophy by leptin. J Biol Chem 287:40441–40447PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Montenegro RM Jr, Montenegro AP, Fernandes MI, de Moraes RR, Elias J Jr, Gouveia LM, Muglia VF, Foss MC, Moreira AC, Martinelli CE Jr (2002) Triglyceride-induced diabetes mellitus in congenital generalized lipodystrophy. J Pediatr Endocrinol Metab 15:441–447CrossRefPubMedGoogle Scholar
  35. 35.
    Musso C, Javor E, Cochran E, Balow JE, Gorden P (2006) Spectrum of renal diseases associated with extreme forms of insulin resistance. Clin J Am Soc Nephrol 1:616–622CrossRefPubMedGoogle Scholar
  36. 36.
    Naska A, Trichopoulou A (2014) Back to the future: the Mediterranean diet paradigm. Nutr Metab Cardiovasc Dis 24:216–219CrossRefPubMedGoogle Scholar
  37. 37.
    Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A (2002) Leptin-replacement therapy for lipodystrophy. N Engl J Med 346:570–578CrossRefPubMedGoogle Scholar
  38. 38.
    Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, Miao L, Tothova Z, Horner JW, Carrasco DR, Jiang S, Gilliland DG, Chin L, Wong WH, Castrillon DH, DePinho RA (2007) FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 128:309–323PubMedCentralCrossRefPubMedGoogle Scholar
  39. 39.
    Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, Cline GW, DePaoli AM, Taylor SI, Gorden P, Shulman GI (2002) Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 109:1345–1350PubMedCentralCrossRefPubMedGoogle Scholar
  40. 40.
    Rother KI, Brown RJ (2013) Novel forms of lipodystrophy: why should we care? Diabetes Care 36:2142–2145PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Saito I, Saruta T, Iyori S, Sakaguchi H (1977) The renal lesion associated with total lipodystrophy. J Am Geriatr Soc 25:175–178CrossRefPubMedGoogle Scholar
  42. 42.
    Seip M (1959) Lipodystrophy and gigantism with associated endocrine manifestations. A new diencephalic syndrome? Acta Paediatr 48:555–574PubMedGoogle Scholar
  43. 43.
    Shastry S, Delgado MR, Dirik E, Turkmen M, Agarwal AK, Garg A (2010) Congenital generalized lipodystrophy, type 4 (CGL4) associated with myopathy due to novel PTRF mutations. Am J Med Genet Part A 152A:2245–2253PubMedCentralCrossRefPubMedGoogle Scholar
  44. 44.
    Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL (1999) Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401:73–76CrossRefPubMedGoogle Scholar
  45. 45.
    Simha V, Rao S, Garg A (2008) Prolonged thiazolidinedione therapy does not reverse fat loss in patients with familial partial lipodystrophy, Dunnigan variety. Diabetes Obes Metab 10:1275–1276CrossRefPubMedGoogle Scholar
  46. 46.
    Simha V, Szczepaniak LS, Wagner AJ, DePaoli AM, Garg A (2003) Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. Diabetes Care 26:30–35CrossRefPubMedGoogle Scholar
  47. 47.
    Strickland LR, Guo F, Lok K, Garvey WT (2013) Type 2 diabetes with partial lipodystrophy of the limbs: a new lipodystrophy phenotype. Diabetes Care 36:2247–2253PubMedCentralCrossRefPubMedGoogle Scholar
  48. 48.
    Subramanyam L, Simha V, Garg A (2010) Overlapping syndrome with familial partial lipodystrophy, Dunnigan variety and cardiomyopathy due to amino-terminal heterozygous missense lamin A/C mutations. Clin Genet 78:66–73PubMedCentralCrossRefPubMedGoogle Scholar
  49. 49.
    Tam CS, Lecoultre V, Ravussin E (2012) Brown adipose tissue: mechanisms and potential therapeutic targets. Circulation 125:2782–2791CrossRefPubMedGoogle Scholar
  50. 50.
    Tsiodras S, Poulia K-A, Yannakoulia M, Chimienti SN, Wadhwa S, Karchmer AW, Mantzoros CS (2009) Adherence to Mediterranean diet is favorably associated with metabolic parameters in HIV-positive patients with the highly active antiretroviral therapy-induced metabolic syndrome and lipodystrophy. Metabolism 58:854–859PubMedCentralCrossRefPubMedGoogle Scholar
  51. 51.
    Turčinov D, Stanley C, Rutherford G, Novotny T, Begovac J (2009) Adherence to the Mediterranean diet is associated with a lower risk of body-shape changes in Croatian patients treated with combination antiretroviral therapy. Eur J Epidemiol 24:267–274PubMedCentralCrossRefPubMedGoogle Scholar
  52. 52.
    Unger RH, Scherer PE (2010) Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol Metab 21:345–352PubMedCentralCrossRefPubMedGoogle Scholar
  53. 53.
    Ursich MJ, Fukui RT, Galvao MS, Marcondes JA, Santomauro AT, Silva ME, Rocha DM, Wajchenberg BL (1997) Insulin resistance in limb and trunk partial lipodystrophy (type 2 Kobberling-Dunnigan syndrome). Metabolism 46:159–163CrossRefPubMedGoogle Scholar
  54. 54.
    Villarroya F, Domingo P, Giralt M (2005) Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. Trends Pharmacol Sci 26:88–93CrossRefPubMedGoogle Scholar
  55. 55.
    Visser ME, Kropman E, Kranendonk ME, Koppen A, Hamers N, Stroes ES, Kalkhoven E, Monajemi H (2011) Characterisation of non-obese diabetic patients with marked insulin resistance identifies a novel familial partial lipodystrophy-associated PPAR gamma mutation (Y151C). Diabetologia 54:1639–1644PubMedCentralCrossRefPubMedGoogle Scholar
  56. 56.
    Weir-Mitchell S (1885) Singular case of absence of adipose matter in upper half of the body. Am J Med Sci 90:105–106CrossRefGoogle Scholar
  57. 57.
    Yano M, Yamamoto T, Nishimura N, Gotoh T, Watanabe K, Ikeda K, Garan Y, Taguchi R, Node K, Okazaki T, Oike Y (2013) Increased oxidative stress impairs adipose tissue function in sphingomyelin synthase 1 null mice. PLoS One 8:e61380PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© University of Navarra 2015

Authors and Affiliations

  1. 1.Department of Nutrition, Diabetes and MetabolismPontificia Universidad Católica de ChileSantiagoChile

Personalised recommendations